Status:

RECRUITING

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

Lead Sponsor:

Tan Tock Seng Hospital

Conditions:

Haloperidol

Advanced Cancer

Eligibility:

All Genders

21-99 years

Phase:

PHASE3

Brief Summary

1. Background and Clinical Need: Delirium is common at the end of life and is challenging to control. There is a clinical need to study the benefits of commonly used drugs like Haloperidol and Ola...

Detailed Description

(A) Background \& Clinical Need Delirium is commonly encountered in palliative care with a prevalence of between 26-74% and rising to as high as 88% nearer the end of life (2). It negatively impacts ...

Eligibility Criteria

Inclusion

  • Patients with advanced cancer or end-stage organ disease
  • Age ≥ 21 years old
  • Fulfil All Three Diagnosis of Delirium:
  • Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria for delirium
  • Memorial Delirium Assessment Scale (MDAS)©1996 \>/= 13
  • Richmond Agitation-Sedation Scale (RASS) Score +1 to +3
  • Able to consume medications orally
  • Prognosis \> 48 hrs (Clinician Estimate)

Exclusion

  • Parkinson's Disease or Vascular Parkinsonism
  • Patient with dementia
  • Chronic Schizophrenia on regular Anti-psychotic medications
  • Taking any regular Benzodiazepines\* or any Anti-psychotic\*\* medications
  • Known allergy to Haloperidol or Olanzapine
  • History of Substance Abuse
  • Known Prolonged corrected QT interval (QTc) Syndrome (In Patient's Medical History)
  • Prognosis \< 48 hours (Clinician's Estimate)
  • Unable to consume oral medications
  • Richmond Agitation and Sedation Scale (RASS) Score +4 (Too agitated and will require Parenteral Anti-psychotics and/or Benzodiazepines)
  • Pregnancy \* e.g. Lorazepam, Alprazolam, Clonazepam, Midazolam \*\*e.g. Haloperidol, Risperidone, Quetiapine, Olanzapine

Key Trial Info

Start Date :

May 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2024

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT04833023

Start Date

May 18 2022

End Date

December 1 2024

Last Update

April 12 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Tan Tock Seng Hospital

Singapore, Singapore, 308433

2

Dover Park Hospice

Singapore, Singapore, 308436

3

St. Andrew's Community Hospital

Singapore, Singapore, 529895